Decoding 5 Analyst Evaluations For IDEXX Laboratories

Throughout the last three months, 5 analysts have evaluated IDEXX Laboratories IDXX, offering a diverse set of opinions from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Insights from analysts' 12-month price targets are revealed, presenting an average target of $502.2, a high estimate of $575.00, and a low estimate of $435.00. This current average has decreased by 11.27% from the previous average price target of $566.00.

Interpreting Analyst Ratings: A Closer Look

The standing of IDEXX Laboratories among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IDEXX Laboratories. This information offers a snapshot of how analysts perceive the current state of the company.
• Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of IDEXX Laboratories compared to the broader market.
• Price Targets: Understanding forecasts, analysts offer estimates for IDEXX Laboratories's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

To gain a panoramic view of IDEXX Laboratories's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on IDEXX Laboratories analyst ratings.

Delving into IDEXX Laboratories's Background

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.

Unraveling the Financial Story of IDEXX Laboratories

Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.

Revenue Growth: IDEXX Laboratories's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 6.56%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.

Net Margin: IDEXX Laboratories's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 23.87% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): IDEXX Laboratories's ROE stands out, surpassing industry averages. With an impressive ROE of 14.56%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): IDEXX Laboratories's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.88% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.62.

Understanding the Relevance of Analyst Ratings

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.